Freenome Health has raised $1.35 billion to date, including a $290 million Series D led by Roche and a $254 million Series E in February 2024 led by T. Rowe Price and Fidelity Investments. Founded in 2014, the U.S.-based company develops AI-driven blood tests for early cancer detection, using deep learning to analyze cell-free DNA and metabolic markers. With over 530 employees and partnerships across the healthcare ecosystem, Freenome is advancing toward FDA approval and large-scale commercialization of its colorectal cancer screening test.